BridgeBio Pharma, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 72 rows in 2020. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-12-28: Reporting owner Turtle Cameron; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-12-28: Reporting owner Turtle Cameron; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-12-28: Reporting owner Turtle Cameron; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-12-15: Reporting owner Sinha Uma; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-12-28 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 255,500 owned after | $17.00 exercise price | $69.48 | 2020-12-29 |
| 2020-12-28 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,000 31,766 owned after | $0.34 exercise price | $69.48 | 2020-12-29 |
| 2020-12-28 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,000 56,042 owned after | $0.16 exercise price | $69.48 | 2020-12-29 |
| 2020-12-15 | Sinha Uma Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,912 8,912 owned after | $3.07 exercise price | $60.99 | 2020-12-17 |
| 2020-12-15 | Sinha Uma Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,832 10,832 owned after | $3.07 exercise price | $60.99 | 2020-12-17 |
| 2020-12-15 | Sinha Uma Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,717 5,717 owned after | $42.80 exercise price | $60.99 | 2020-12-17 |
| 2020-12-15 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,456 4,456 owned after | $3.07 exercise price | $60.99 | 2020-12-17 |
| 2020-12-15 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,137 3,137 owned after | $3.07 exercise price | $60.99 | 2020-12-17 |
| 2020-12-15 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +2,199 2,199 owned after | $42.80 exercise price | $60.99 | 2020-12-17 |
| 2020-12-15 | SCHELLER RICHARD H Director, Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −29,277 53,388 owned after | $17.00 exercise price | $60.99 | 2020-12-17 |
| 2020-12-01 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 8,282 owned after | $1.05 exercise price | $51.13 | 2020-12-02 |
| 2020-11-25 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −742 263,000 owned after | $17.00 exercise price | $48.47 | 2020-11-25 |
| 2020-11-24 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,258 263,742 owned after | $17.00 exercise price | $46.98 | 2020-11-25 |
| 2020-11-16 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 18,282 owned after | $1.05 exercise price | $44.33 | 2020-11-18 |
| 2020-11-05 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 268,000 owned after | $17.00 exercise price | $40.99 | 2020-11-09 |
| 2020-11-02 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 28,282 owned after | $1.05 exercise price | $38.57 | 2020-11-03 |
| 2020-10-16 | HOMCY CHARLES J Director, Officer (Chairman of Pharmaceuticals) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,256 260,207 owned after | $17.00 exercise price | $40.97 | 2020-10-19 |
| 2020-10-01 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,236 0 owned after | $0.28 exercise price | $39.60 | 2020-10-05 |
| 2020-10-01 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,019 0 owned after | $0.28 exercise price | $39.60 | 2020-10-05 |
| 2020-10-01 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,745 38,282 owned after | $1.05 exercise price | $39.60 | 2020-10-05 |
| 2020-09-30 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 270,500 owned after | $17.00 exercise price | $37.52 | 2020-10-02 |
| 2020-09-30 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,000 62,042 owned after | $0.16 exercise price | $37.52 | 2020-10-02 |
| 2020-09-30 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,000 37,766 owned after | $0.34 exercise price | $37.52 | 2020-10-02 |
| 2020-09-30 | HOMCY CHARLES J Director, Officer (Chairman of Pharmaceuticals) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 270,463 owned after | $17.00 exercise price | $37.52 | 2020-10-01 |
| 2020-09-18 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 273,000 owned after | $17.00 exercise price | $42.19 | 2020-09-22 |
| 2020-09-18 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,901 4,586 owned after | $0.16 exercise price | $42.19 | 2020-09-22 |
| 2020-09-18 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,099 2,236 owned after | $0.28 exercise price | $42.19 | 2020-09-22 |
| 2020-09-15 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 275,500 owned after | $17.00 exercise price | $36.99 | 2020-09-16 |
| 2020-09-11 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,000 43,766 owned after | $0.34 exercise price | $33.56 | 2020-09-15 |
| 2020-09-01 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 9,487 owned after | $0.16 exercise price | $27.62 | 2020-09-03 |
| 2020-08-03 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 19,487 owned after | $0.16 exercise price | $27.20 | 2020-08-05 |
| 2020-07-01 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 29,487 owned after | $0.16 exercise price | $30.34 | 2020-07-06 |
| 2020-06-30 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,000 68,042 owned after | $0.16 exercise price | $32.61 | 2020-07-02 |
| 2020-06-30 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,000 45,766 owned after | $0.34 exercise price | $32.61 | 2020-07-02 |
| 2020-06-23 | Scott Randal W Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +101,223 101,223 owned after | $32.62 exercise price | $32.62 | 2020-06-25 |
| 2020-06-23 | SAUNDERS BRENT L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +101,223 101,223 owned after | $32.62 exercise price | $32.62 | 2020-06-25 |
| 2020-06-23 | Lo Andrew Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +101,223 101,223 owned after | $32.62 exercise price | $32.62 | 2020-06-25 |
| 2020-06-03 | YAU YI CHING Officer (Chief Accounting Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,931 45,931 owned after | $28.86 exercise price | $28.86 | 2020-06-05 |
| 2020-06-03 | STEPHENSON BRIAN C Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +196,850 196,850 owned after | $28.86 exercise price | $28.86 | 2020-06-05 |
| 2020-06-03 | Stolz Brian M. Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +183,727 183,727 owned after | $28.86 exercise price | $28.86 | 2020-06-05 |
| 2020-06-03 | Kumar Neil Director, Officer (CEO and President) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +590,551 590,551 owned after | $28.86 exercise price | $28.86 | 2020-06-05 |
| 2020-06-02 | Cook Jennifer E. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +112,422 112,422 owned after | $29.00 exercise price | $29.00 | 2020-06-04 |
| 2020-06-02 | HOMCY CHARLES J Director, Officer (Chairman of Pharmaceuticals) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +112,422 112,422 owned after | $29.00 exercise price | $29.00 | 2020-06-04 |
| 2020-06-02 | MOMTAZEE JAMES C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +112,422 112,422 owned after | $29.00 exercise price | $29.00 | 2020-06-04 |
| 2020-06-02 | Satvat Ali J. Director, 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +112,422 112,422 owned after | $29.00 exercise price | $29.00 | 2020-06-04 |
| 2020-06-02 | SCHELLER RICHARD H Director, Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +112,422 112,422 owned after | $29.00 exercise price | $29.00 | 2020-06-04 |
| 2020-06-02 | AGUIAR ERIC Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +112,422 112,422 owned after | $29.00 exercise price | $29.00 | 2020-06-04 |
| 2020-05-26 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −18,365 0 owned after | $1.05 exercise price | $35.32 | 2020-05-27 |
| 2020-05-19 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,335 7,335 owned after | $0.28 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,019 1,019 owned after | $0.28 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +39,487 39,487 owned after | $0.16 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,778 7,778 owned after | $4.13 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,351 3,351 owned after | $1.65 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +13,932 13,932 owned after | $4.22 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,027 45,027 owned after | $1.05 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,271 19,271 owned after | $2.29 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | HENDERSON MICHAEL THOMAS Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,365 18,365 owned after | $1.05 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,082 1,082 owned after | $1.25 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +74,042 74,042 owned after | $0.16 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +49,766 49,766 owned after | $0.34 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | Sinha Uma Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,366 5,366 owned after | $1.25 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | Sinha Uma Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +49,361 49,361 owned after | $0.16 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | Sinha Uma Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +49,765 49,765 owned after | $0.34 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | Sinha Uma Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,022 3,022 owned after | $3.35 exercise price | $34.50 | 2020-05-21 |
| 2020-05-19 | MCCORMICK FRANK Officer (Chairman of Oncology) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,549 10,549 owned after | $1.05 exercise price | $34.50 | 2020-05-21 |
| 2020-04-27 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,000 278,000 owned after | $17.00 exercise price | $31.74 | 2020-04-29 |
| 2020-04-08 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,000 280,000 owned after | $17.00 exercise price | $26.93 | 2020-04-10 |
| 2020-02-12 | DANIELS RONALD J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +91,554 91,554 owned after | $34.65 exercise price | $34.65 | 2020-02-14 |
| 2020-02-12 | MOMTAZEE JAMES C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,927 24,927 owned after | $34.65 exercise price | $34.65 | 2020-02-14 |
| 2020-02-11 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,000 288,000 owned after | $17.00 exercise price | $34.84 | 2020-02-13 |
| 2020-01-14 | HOMCY CHARLES J Director, Officer (Chairman of Pharmaceuticals) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 280,463 owned after | $17.00 exercise price | $34.58 | 2020-01-16 |
| 2020-01-08 | Turtle Cameron Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 290,000 owned after | $17.00 exercise price | $34.18 | 2020-01-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |